Zevalin Market Report 2026

Zevalin Market Overview

• The Zevalin market growth in the historic period has been driven by advancement of monoclonal antibody development, expansion of nuclear medicine capabilities • Market expansion is supported by increasing investments in targeted cancer therapies, growing demand for personalized oncology solutions • Growth Driver: Rising Incidence Of Non-Hodgkin’s Lymphoma Drives Growth In The Market • North America was the largest region in 2025.

What Is Covered Under Zevalin Market?

Zevalin (ibritumomab tiuxetan) is a monoclonal antibody used to treat non-Hodgkin lymphoma. It is a radiolabeled therapy that combines an antibody with yttrium-90, a radioactive substance, to target and destroy cancer cells. This targeted radiation helps slow lymphoma growth while minimizing harm to healthy tissues. The main types of indication for zevalin are relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) and previously untreated follicular non-Hodgkin lymphoma (NHL). Relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) refers to NHL that has either recurred after initial therapy (relapsed) or is resistant to further treatment (refractory). It is formulated in various formulations, such as in-111 Zevalin and Y-90 Zevalin, and it is distributed through several distribution channels, including hospitals, specialty pharmacies, and online pharmacies. It is used by various end users, such as adult patients and geriatric patients.

What Is The Zevalin Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in targeted cancer therapies, growing demand for personalized oncology solutions, expansion of radiopharmaceutical infrastructure, rising focus on treatment efficacy with reduced toxicity, continued innovation in antibody-based cancer treatments. Major trends in the forecast period include increasing adoption of targeted radioimmunotherapy, growing use of precision oncology approaches, expansion of lymphoma-specific treatment protocols, enhanced integration of nuclear medicine infrastructure, rising focus on treatment selectivity.

Global Zevalin Market Segmentation

1) By Indication: Relapsed Or Refractory Low-Grade Non-Hodgkin Lymphoma (NHL), Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) 2) By Formulation: In-111 Zevalin, Y-90 Zevalin 3) By Distribution Channel: Hospitals, Specialty Pharmacies, Online Pharmacies 4) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Zevalin Market?

The rising incidence of non-Hodgkin’s lymphoma is set to propel growth of the zevalin market moving forward. Non-Hodgkin lymphoma is a range of blood cancers that start in lymphocytes and impact the lymphatic system and immune system. The incidence of non-Hodgkin lymphoma is attributed to various factors, including an aging population, increased exposure to risk factors such as immunosuppression, as well as environmental influences and lifestyle changes. Zevalin is a monoclonal antibody that targets CD20, a protein on B-cells commonly affected in non-Hodgkin’s lymphoma. It delivers targeted radiation to destroy cancerous B-cells, shrinking tumors and increasing the likelihood of remission. For instance, in January 2024, according to a report published by the American Cancer Society, Inc., a US-based nonprofit organization, non-Hodgkin lymphoma is among the most prevalent cancers in the United States, representing approximately 4% of all new cancer cases. In 2024, an estimated 80,620 individuals will be diagnosed, including 44,590 males and 36,030 females. Therefore, the rising incidence of non-Hodgkin’s lymphoma is driving the growth of the zevalin industry. The growth in healthcare infrastructure is significantly driving the growth of the zevalin market in the future. Healthcare infrastructure involves the facilities, systems, equipment, and workforce that support the provision of healthcare services. The growth in healthcare infrastructure is driven by factors such as an aging population, rising demand for quality healthcare services, increased government investment and support, and advancements in medical technology. The expansion of healthcare infrastructure is improving access to advanced cancer treatments, making zevalin more vital in treating cancer, and its targeted radioimmunotherapy enhances patient outcomes in a stronger healthcare system. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the growth in healthcare infrastructure is driving the growth of the zevalin industry. Growth in the geriatric population is expected to propel the growth of the zevalin market going forward. The geriatric population consists of individuals aged 65 and older, who typically need specialized medical care due to age-related health challenges. The growth in the geriatric population is primarily driven by increased life expectancy, declining fertility rates, and improved healthcare access. Zevalin offers a targeted, less invasive treatment option, making it ideal for older patients with underlying health conditions. It minimizes side effects and enhances outcomes, improving their quality of life. For instance, in July 2024, according to the House of Commons Library, a UK-based government agency, there are approximately 33 individuals aged 65 and over for every 100 people aged 20 to 64 in the UK, and in 2022 this amounted to around 12.7 million people aged 65 or older, representing 19% of the population, with projections indicating a rise to 22.1 million, or 27% of the population, by 2072. Therefore, the growth in the geriatric population is driving the growth of the zevalin industry.

Key Players In The Global Zevalin Market

Major companies operating in the zevalin market are Acrotech Biopharma Inc.

Regional Insights

North America was the largest region in the zevalin market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zevalin Market?

The zevalin market consists of sales of injections, radiolabeled therapy kits, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zevalin Market Report 2026?

The zevalin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zevalin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.